ClinicalTrials.gg
Not yet recruitingNCT07550257Updated Apr 24, 2026

Prospective Registry of Acute Ischemic Stroke in Children Under 18 Years Old in China

An observational study in Acute Ischemic Stroke (AIS), Pediatric Stroke, sponsored by Gansu Provincial Maternal and Child Health Care Hospital. Not yet recruiting. Open to participants aged 28 Days to 18 Years. Per ClinicalTrials.gov, last updated 2026-04-24.

Sponsored by Gansu Provincial Maternal and Child Health Care Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
28 Days to 18 Years
Sex
All
01

Study summary

This observational study aims to investigate the real-world effectiveness and safety of different treatment strategies for acute ischemic stroke (AIS) in Chinese children under 18 years of age.

Its primary research question is: In real-world clinical practice, does endovascular therapy (e.g., stent retriever thrombectomy, aspiration thrombectomy) improve 90-day functional outcomes in pediatric AIS patients with acute anterior or posterior circulation large vessel occlusion? Children under 18 years of age receiving routine AIS diagnosis and treatment at approximately 25-35 study centers across China will undergo neurological function assessments, imaging examinations, and evaluations of growth, development, and psychosocial status at baseline, 24 hours post-procedure, 7 days post-procedure or at hospital discharge, and at 90 days and 6 months post-onset. Adverse events will also be documented.

02

Conditions studied

  • Acute Ischemic Stroke (AIS), Pediatric Stroke

Browse trials for

03

In context

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

This study's planned enrollment of 1,000 is above the median of 300 across 776 observational studies indexed under Ischemic Stroke.

Browse Ischemic Stroke studies →

Lead sponsor

Gansu Provincial Maternal and Child Health Care Hospital is the lead sponsor of 3 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
28 Days to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This study will prospectively enroll consecutive patients aged 28 days to \<18 years with acute ischemic stroke (AIS) from approximately 25-35 participating centers across China. Eligible patients must have first-ever stroke with onset ≤7 days prior to admission, confirmed by computed tomography (CT) or magnetic resonance imaging (MRI). Both patients receiving standard medical therapy alone and those receiving endovascular treatment (including stent retrieval, aspiration thrombectomy, balloon angioplasty, stenting, or intra-arterial thrombolysis) will be included. Patients with lack of imaging confirmation, history of hypoxic-ischemic encephalopathy, ischemic stroke caused by cerebral venous system, or concurrent indistinguishable ischemic and hemorrhagic stroke will be excluded. The study aims to enroll a target sample size of >1000 patients.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >28 days and \<18 years;
  • Presence of stroke-related symptoms (hemiparesis, facial palsy, aphasia, altered level of consciousness, seizure, headache) or atypical symptoms (sudden lethargy or irritability, crying, feeding difficulties, incontinence, sensory loss, ataxia, vertigo, nausea and/or vomiting, neck pain, fever);
  • First-ever stroke and onset within ≤7 days prior to admission;
  • Acute ischemic stroke confirmed by computed tomography (CT) or magnetic resonance imaging (MRI);
  • Legal guardian provides signed ;
  • For children aged ≥8 years to \<18 years who are conscious and without comprehension impairment, assent obtained from the child;

Exclusion criteria

Exclusion Criteria:

  • Lack of imaging examination or stroke diagnosed without imaging
  • History of hypoxic-ischemic encephalopathy
  • Ischemic stroke caused by cerebral venous system
  • Concurrent presence of indistinguishable ischemic and hemorrhagic stroke
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • All eligible children aged 28 days to <18 years with acute ischemic stroke (AIS) enrolled consecutiv

    All eligible children aged 28 days to \<18 years with acute ischemic stroke (AIS) enrolled consecutively from approximately 25-35 participating centers in China. Patients receive standard clinical management without treatment restrictions. Data collected include baseline demographics, clinical presentation, treatment strategies (medical therapy alone or endovascular treatment including stent retrieval, aspiration, balloon angioplasty, stenting, or intra-arterial thrombolysis), imaging parameters, safety outcomes, and functional outcomes assessed by pediatric modified Rankin Scale (ped-mRS) at 90 days and 6 months.

    Other: Standard Clinical Management

Interventions

  • OtherStandard Clinical Management

    Participants receive routine clinical care per each center's standard practice. Treatment may include medical therapy (antiplatelet agents, anticoagulation) and/or endovascular treatment (stent retriever, aspiration thrombectomy, balloon angioplasty, stenting, or intra-arterial thrombolysis), as determined by the treating physician. No protocol-mandated intervention is applied.

06

What researchers measure

Primary outcomes

  1. Pediatric Modified Rankin Scale (ped-mRS) Score at 90 Days

    Primary Outcome Measure assessed by the pediatric modified Rankin Scale (ped-mRS) at 90 days (±7 days) post-stroke onset. The ped-mRS is a 7-point ordinal scale (0=no symptoms to 6=death). The full ordinal distribution of scores will be analyzed as the primary efficacy endpoint.

    Time frame: 90 days (±7 days) post-stroke onset

Secondary outcomes

  1. Proportion of Patients with ped-mRS 0-1, 0-2, 0-3 at 90 Days

    Proportion of patients achieving favorable functional outcome, defined as pediatric modified Rankin Scale (ped-mRS) score of 0-1, 0-2, 0-3 at 90 days (±7 days) post-stroke onset.

    Time frame: 90 days (±7 days) post-stroke onset

  2. Change in ped-NIHSS Score at 24 Hours

    Change in pediatric National Institutes of Health Stroke Scale (ped-NIHSS) score from baseline to 24 hours (±12 hours) post-admission/post-procedure. Higher scores indicate more severe stroke.

    Time frame: 24 hours (±12 hours) post-procedure

  3. Pediatric Modified Rankin Scale (ped-mRS) Score at 6 Months

    Functional outcome assessed by ped-mRS at 6 months (±14 days) post-stroke onset. The scale ranges from 0 (no symptoms) to 6 (death).

    Time frame: 6 months (±14 days) post-stroke onset

Other outcomes

  1. Target Vessel Final Recanalization Rate (eTICI 2b-3) on DSA

    Proportion of endovascular-treated patients achieving extended Thrombolysis in Cerebral Infarction (eTICI) grade 2b-3 on final digital subtraction angiography (DSA) assessment. eTICI 2b indicates ≥50% reperfusion, eTICI 3 indicates 100% reperfusion.

    Time frame: immediately post-procedure

  2. Target Vessel Recanalization Rate on CTA/MRA/DSA at 7 Days or Discharge

    Proportion of endovascular-treated patients achieving target vessel recanalization assessed by CTA, MRA, or DSA at 7 days (±1 day) post-procedure or at discharge.

    Time frame: 7 days (±1 day) post-procedure or at discharge

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Chandra RV, Leslie-Mazwi TM, Mehta BP, Derdeyn CP, Demchuk AM, Menon BK, Goyal M, Gonzalez RG, Hirsch JA. Does the use of IV tPA in the current era of rapid and predictable recanalization by mechanical embolectomy represent good value? J Neurointerv Surg. 2016 May;8(5):443-6. doi: 10.1136/neurintsurg-2015-012231. Epub 2016 Jan 12. PubMed 26758911 ↗
  • Puetz V, Khomenko A, Hill MD, Dzialowski I, Michel P, Weimar C, Wijman CA, Mattle HP, Engelter ST, Muir KW, Pfefferkorn T, Tanne D, Szabo K, Kappelle LJ, Algra A, von Kummer R, Demchuk AM, Schonewille WJ; Basilar Artery International Cooperation Study (BASICS) Group. Extent of hypoattenuation on CT angiography source images in basilar artery occlusion: prognostic value in the Basilar Artery International Cooperation Study. Stroke. 2011 Dec;42(12):3454-9. doi: 10.1161/STROKEAHA.111.622175. Epub 2011 Sep 29. PubMed 21960577 ↗
  • Barber PA, Demchuk AM, Zhang J, Buchan AM. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. Alberta Stroke Programme Early CT Score. Lancet. 2000 May 13;355(9216):1670-4. doi: 10.1016/s0140-6736(00)02237-6. PubMed 10905241 ↗
  • Goyal M, Fargen KM, Turk AS, Mocco J, Liebeskind DS, Frei D, Demchuk AM. 2C or not 2C: defining an improved revascularization grading scale and the need for standardization of angiography outcomes in stroke trials. J Neurointerv Surg. 2014 Mar;6(2):83-6. doi: 10.1136/neurintsurg-2013-010665. Epub 2013 Feb 6. No abstract available. PubMed 23390038 ↗
  • Zhang W, Zhu B, Cai G, Niu M, Duan C, Zhang P, Xu Y, Xiao L, Li Q, Su Z, Wu F, Li W, Wang H, Sun W. Current status and prognostic factors of paediatric arterial ischaemic stroke in China: a study protocol for Chinese Paediatric Ischaemic Stroke Registry (CPISR). BMJ Open. 2025 Jun 18;15(6):e093718. doi: 10.1136/bmjopen-2024-093718. PubMed 40533220 ↗
  • Tudorache R, Kossorotoff M, Kerleroux B, Denier C, Naggara O, Boulouis G; KID-CLOT Group. Determinants of Timely Access to Recanalization Treatments and Outcomes in Pediatric Ischemic Stroke. Stroke. 2024 Nov;55(11):2716-2719. doi: 10.1161/STROKEAHA.124.046417. Epub 2024 Oct 1. PubMed 39351662 ↗
  • Sporns PB, Bhatia K, Abruzzo T, Pabst L, Fraser S, Chung MG, Lo W, Othman A, Steinmetz S, Jensen-Kondering U, Schob S, Kaiser DPO, Marik W, Wendl C, Kleffner I, Henkes H, Kraehling H, Nguyen-Kim TDL, Chapot R, Yilmaz U, Wang F, Hafeez MU, Requejo F, Limbucci N, Kauffmann B, Mohlenbruch M, Nikoubashman O, Schellinger PD, Musolino P, Alawieh A, Wilson J, Grieb D, Gersing AS, Liebig T, Olivieri M, Schwabova JP, Tomek A, Papanagiotou P, Boulouis G, Naggara O, Fox CK, Orlov K, Kuznetsova A, Parra-Farinas C, Muthusami P, Regenhardt RW, Dmytriw AA, Burkard T, Martinez M, Brechbuhl D, Steinlin M, Sun LR, Hassan AE, Kemmling A, Lee S, Fullerton HJ, Fiehler J, Psychogios MN, Wildgruber M. Endovascular thrombectomy for childhood stroke (Save ChildS Pro): an international, multicentre, prospective registry study. Lancet Child Adolesc Health. 2024 Dec;8(12):882-890. doi: 10.1016/S2352-4642(24)00233-5. Epub 2024 Oct 11. PubMed 39401507 ↗
  • Sporns PB, Fullerton HJ, Lee S, Kirton A, Wildgruber M. Current treatment for childhood arterial ischaemic stroke. Lancet Child Adolesc Health. 2021 Nov;5(11):825-836. doi: 10.1016/S2352-4642(21)00167-X. Epub 2021 Jul 29. PubMed 34331864 ↗
  • 中华医学会儿科学分会神经学组. 儿童动脉缺血性脑卒中诊疗专家共识[J]. 中华儿科杂志, 2022, 60(12): 1248-1252.

Individual participant data

Plan to share: No — Due to ethical and regulatory restrictions: enrollment of pediatric participants (age \<18 years), collection of sensitive clinical, imaging, and biospecimen data (blood and thrombus samples), and compliance with Chinese human genetic resources management regulations. Informed consent obtained does not include provisions for public sharing of individual participant data.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for May 2029, 35 months later.

Of 401 non-industry observational studies under Ischemic Stroke, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 140. This study's planned 35 months is below that.

Counting every sponsor, half of 443 studies reached it within 53 months; a quarter within 24 and three quarters within 127.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2026
First posted
Apr 24, 2026
StartEst.
Jun 1, 2026
Primary completionEst.
May 31, 2029
CompletionEst.
Dec 31, 2029
Last update
Apr 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07550257
Lead sponsor
Gansu Provincial Maternal and Child Health Care Hospital
Responsible party
Sponsor
First posted
Apr 24, 2026
Start date
Jun 1, 2026 (estimated)
Primary completion
May 31, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Apr 24, 2026

Study contacts

Jian Liu President, Gansu Provincial Maternity and Child-Care Hospital, MD
Contact
Medecinliu@sina.com
+86 13609354197
Rong Yin Chief, Division of Neurology, MD
Contact
yin_rong_@163.com
+83 13919930466

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion